Head to Head Comparison: Metagenomi (NASDAQ:MGX) versus Cardiol Therapeutics (NASDAQ:CRDL)

Metagenomi (NASDAQ:MGX) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Valuation and Earnings

This table compares Metagenomi and Cardiol Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$55.08 million	1.39	-$68.25 million	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$20.84 million	($0.39)	-2.95

Cardiol Therapeutics has lower revenue, but higher earnings than Metagenomi.

Profitability

This table compares Metagenomi and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-134.27%	-43.23%	-18.86%
Cardiol Therapeutics	N/A	-194.40%	-129.07%

Analyst Ratings

This is a summary of recent ratings and target prices for Metagenomi and Cardiol Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	0	1	6	0	2.86
Cardiol Therapeutics	0	0	5	2	3.29

Metagenomi presently has a consensus price target of $16.67, indicating a potential upside of 713.01%. Cardiol Therapeutics has a consensus price target of $8.40, indicating a potential upside of 630.43%. Given Metagenomi’s higher probable upside, equities analysts clearly believe Metagenomi is more favorable than Cardiol Therapeutics.

Insider and Institutional Ownership

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cardiol Therapeutics beats Metagenomi on 6 of the 11 factors compared between the two stocks.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.